Could a supplement combo slow ALS? new trial launches
NCT ID NCT07414212
First seen Feb 19, 2026 · Last updated May 21, 2026 · Updated 13 times
Summary
This study tests whether adding N-acetylcysteine (NAC) and EH-301 to standard riluzole treatment can slow down or improve symptoms in people with ALS. About 90 participants with early-stage ALS will receive either the active combination or a placebo for 6 months, followed by an optional 6-month period where everyone gets the active treatment. The goal is to see if this combination helps maintain daily function and muscle strength.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario Donostia
RECRUITINGSan Sebastián, Guipuzcoa, 20003, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.